文献速递主动脉疾病

使用新型低剖面开窗定制腹主动脉覆膜支架系统腔内修复近肾及肾旁腹主动脉瘤:技术细节与短期结果

Endovascular Repair of Juxtarenal and Pararenal Abdominal Aortic Aneurysms Using a Novel Low-Profile Fenestrated Custom-Made Endograft: Technical Details and Short-Term Outcomes.
PubMed 文献 · J Endovasc Ther · 2024-01-30

该研究纳入4家欧洲高容量学术医学中心2021年6月至2023年9月收治的42例近肾及肾旁腹主动脉瘤患者,使用新型定制开窗TREO®腹主动脉覆膜支架系统进行腔内修复。技术成功率为90%,围手术期死亡1例,随访中另3例死于非动脉瘤相关原因,短期死亡率和并发症率低。

要点

  • 42例近肾及肾旁腹主动脉瘤患者使用定制开窗TREO®支架系统,技术成功率为90%。
  • 术后首次CT血管造影见19例内漏:1b型1例(2%)、2型15例(36%)、3型3例。
  • 住院期间1例动脉瘤相关死亡,2例肢体闭塞需再干预;随访中3例死于非动脉瘤相关原因。

核心结论

  • 在欧洲首次使用定制开窗TREO®腹主动脉覆膜支架系统的结果令人鼓舞,这些患者中17%既往接受过腹主动脉瘤修复,短期死亡率和并发症率低。
  • 需要中期和长期随访数据来评估内支架的耐久性和性能。

研究设计与样本

  • 研究纳入2021年6月至2023年9月来自4家欧洲高容量学术医学中心的近肾及肾旁腹主动脉瘤患者,均使用定制开窗TREO®腹主动脉覆膜支架系统治疗。
  • 分析技术成功以及30天/住院期间死亡率和并发症;技术成功定义为成功腔内植入支架且靶血管前向血流保留,术后首次CT血管造影无1型或2型内漏。
  • 共纳入42例连续患者。

主要发现

  • 大多数装置构造为2个(N=4;9.5%)、3个(N=9;21.4%)或4个(N=27;64%)开窗;1例装置为单开窗(2.4%),1例装置含5个开窗(2.4%);17%既往接受过腹主动脉瘤修复。
  • 中位随访101(2-620)天期间,另有3例患者死于非动脉瘤相关原因;技术成功率达到90%。
  • 术后首次CT扫描见19例内漏:1b型1例(N=1;2%)、2型15例(N=15;36%)、3型3例(N=3%)。
  • 中位随访361(82-620)天期间,11例患者接受了超过1次CT扫描:3例2型内漏消退,1例3型内漏在该期间得到治疗;随访中1例患者出现凝血障碍导致分支闭塞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要中期和长期随访数据来评估内支架的耐久性和性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study is to share preliminary experiences and outcomes with a novel custom-made fenestrated TREO® Abdominal Stent-Graft System to treat juxtarenal and pararenal abdominal aortic aneurysms (AAAs). METHODS: Juxtarenal and pararenal AAA patients treated with the custom-made fenestrated TREO® Abdominal Stent-Graft System were included from 4 high-volume European academic medical centers from June 2021 to September 2023. Technical success and 30-day/in-hospital mortality and complications were analyzed. Technical success was defined as successful endovascular implantation of the stent graft with preservation of antegrade flow to the target vessels, and absence of type 1 or 2 endoleak (EL) at the first postoperative computed tomography angiography (CTA). RESULTS: Forty-two consecutive patients were included. The majority of the devices were constructed with 2 (N=4; 9.5%), 3 (N=9; 21.4%), or 4 (N=27; 64%) fenestrations. In 1 case, the device was constructed with a single fenestration (2.4%) and 1 device contained 5 fenestrations (2.4%); 17% had previous AAA repair. Target vessel cannulation with placement of a bridging stent was successful in all but 1 vessel (99, 3%). One aneurysm-related death occurred in the direct postoperative period and 2 limb occlusions necessitated reintervention during admission. In the median follow-up period of 101 (2-620) days, 3 more patients died due to non-aneurysm-related causes. Technical success was achieved in 90% of the cases. Nineteen ELs were seen on the first postoperative CT scan: 1 type 1b EL (N=1; 2%), 15 type 2 ELs (N=15; 36%), and 3 type 3 ELs (N=3%). Eleven patients received more than 1 CT scan during a median follow-up of 361 days (82-620): 3 type 2 ELs resolved and 1 type 3 EL was treated in this period. In the follow-up, 1 patient had a coagulation disorder that caused occlusions of the branches. CONCLUSION: The results of the first experiences using the custom-made fenestrated TREO® Abdominal Stent-Graft System in Europe are promising. There was a low short-term mortality and morbidity rate in these patients of which 17% had previous AAA repair. Mid-term and long-term follow-up data are needed to evaluate endograft durability and performance.Clinical ImpactThis study shows the first experiences and short-term results of a novel low-profile custom-made device: the custom-made fenestrated TREO® Abdominal Stent-Graft System. Showing these results and experiences can help the physicians in clinical decision-making for their patients.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Yeung KK, Nederhoed JH, Tran BL, et al. Endovascular Repair of Juxtarenal and Pararenal Abdominal Aortic Aneurysms Using a Novel Low-Profile Fenestrated Custom-Made Endograft: Technical Details and Short-Term Outcomes. J Endovasc Ther. 2024. PMID: 38288587. doi:10.1177/15266028241227392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。